Baar J - Search Results

1

Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.

Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW 2nd, Clark JI, Baar J, Sosman J, Weber J, Lathia C, Brunetti J, Cihon F, Schwartz B. Margolin K, et al. Among authors: baar j. Clin Cancer Res. 2007 Jun 1;13(11):3312-9. doi: 10.1158/1078-0432.CCR-06-1341. Clin Cancer Res. 2007. PMID: 17545537 Clinical Trial.

2

A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.

Baar J, Silverman P, Lyons J, Fu P, Abdul-Karim F, Ziats N, Wasman J, Hartman P, Jesberger J, Dumadag L, Hohler E, Leeming R, Shenk R, Chen H, McCrae K, Dowlati A, Remick SC, Overmoyer B. Baar J, et al. Clin Cancer Res. 2009 May 15;15(10):3583-90. doi: 10.1158/1078-0432.CCR-08-2917. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417018 Free PMC article. Clinical Trial.

3

Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma.

Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J. Whiteside TL, et al. Among authors: baar j. Clin Cancer Res. 2003 Feb;9(2):641-9. Clin Cancer Res. 2003. PMID: 12576430 Clinical Trial.

4

Analyzing the same data in two ways: a demonstration model to illustrate the reporting and misreporting of clinical trials.

Baar J, Tannock I. Baar J, et al. J Clin Oncol. 1989 Jul;7(7):969-78. doi: 10.1200/JCO.1989.7.7.969. J Clin Oncol. 1989. PMID: 2738626

5

MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.

Siroy A, Abdul-Karim FW, Miedler J, Fong N, Fu P, Gilmore H, Baar J. Siroy A, et al. Among authors: baar j. Hum Pathol. 2013 Oct;44(10):2159-66. doi: 10.1016/j.humpath.2013.04.010. Epub 2013 Jul 8. Hum Pathol. 2013. PMID: 23845471 Free PMC article.

6

Biological therapy of breast cancer: recent clinical applications.

Baar J. Baar J. Curr Opin Investig Drugs. 2007 Dec;8(12):987-95. Curr Opin Investig Drugs. 2007. PMID: 18058569

7

Optimized systemic dosing with CpG DNA enhances dendritic cell-mediated rejection of a poorly immunogenic mammary tumor in BALB/c mice.

Cai Q, Kublo L, Cumberland R, Gooding W, Baar J. Cai Q, et al. Among authors: baar j. Clin Transl Sci. 2009 Feb;2(1):62-6. doi: 10.1111/j.1752-8062.2008.00073.x. Clin Transl Sci. 2009. PMID: 20443869 Free PMC article.

8

Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response.

Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman F, Schiff D, Attanucci J, Edington H, Chambers W, Robbins P, Baar J, Kinzler D, Whiteside T, Elder E. Okada H, et al. Among authors: baar j. Hum Gene Ther. 2000 Mar 1;11(4):637-53. doi: 10.1089/10430340050015824. Hum Gene Ther. 2000. PMID: 10724042 Clinical Trial. No abstract available.

9

Clinical applications of dendritic cell cancer vaccines.

Baar J. Baar J. Oncologist. 1999;4(2):140-4. Oncologist. 1999. PMID: 10337385 Free article. Review. No abstract available.

10

Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.

Tüting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff CL Jr, Wagner SN, van der Bruggen P, Baar J, Lotze MT, Storkus WJ. Tüting T, et al. Among authors: baar j. J Immunol. 1998 Feb 1;160(3):1139-47. J Immunol. 1998. PMID: 9570527

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

69 results

Search Page